Spironolactone: An Anti-androgenic and Anti-hypertensive Drug That May Provide Protection Against the Novel Coronavirus (SARS-CoV-2) Induced Acute Respiratory Distress Syndrome (ARDS) in COVID-19

Flavio A Cadegiani; Carlos G Wambier; Andy Goren

doi:10.3389/fmed.2020.00453

Spironolactone: An Anti-androgenic and Anti-hypertensive Drug That May Provide Protection Against the Novel Coronavirus (SARS-CoV-2) Induced Acute Respiratory Distress Syndrome (ARDS) in COVID-19

Front Med (Lausanne). 2020 Jul 28:7:453. doi: 10.3389/fmed.2020.00453. eCollection 2020.

Authors

Flavio A Cadegiani^{1

2}, Carlos G Wambier³, Andy Goren^{3

4}

Affiliations

¹ Department of Endocrinology, Federal University of São Paulo, São Paulo, Brazil.
² Corpometria Institute, Brasília, Brazil.
³ Department of Dermatology, Warren Alpert Medical School of Brown University, Providence, RI, United States.
⁴ Applied Biology Inc., Irvine, CA, United States.

No abstract available

Keywords: ARDS (acute respiratory distress syndrome); COVID-19; SARS-CoV-2; TMPRSS2; androgen receptor antagonist; coronavirus; pandemic; spironolactone.